17.31
0.31 (1.82%)
| Previous Close | 17.00 |
| Open | 17.06 |
| Volume | 76,996 |
| Avg. Volume (3M) | 419,780 |
| Market Cap | 6,182,530,048 |
| Price / Earnings (Forward) | 14.56 |
| Price / Sales | 1.12 |
| Price / Book | 0.940 |
| 52 Weeks Range | |
| Earnings Date | 28 Oct 2026 |
| Profit Margin | -7.50% |
| Operating Margin (TTM) | -5.36% |
| Diluted EPS (TTM) | -1.02 |
| Quarterly Revenue Growth (YOY) | 3.50% |
| Total Debt/Equity (MRQ) | 75.07% |
| Current Ratio (MRQ) | 1.56 |
| Operating Cash Flow (TTM) | 166.00 M |
| Levered Free Cash Flow (TTM) | 69.00 M |
| Return on Assets (TTM) | 0.61% |
| Return on Equity (TTM) | -5.36% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Bullish | Mixed | |
| Stock | Bausch + Lomb Corporation | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -2.0 |
| Price Volatility | -3.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.25 |
|
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Mid Core |
| % Held by Insiders | 88.13% |
| % Held by Institutions | 10.97% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Caspian Capital Lp | 30 Jun 2026 | 1,999,043 |
| Clark Estates Inc/Ny | 30 Jun 2026 | 881,000 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BAILEY A ROBERT D | 16.76 | - | 33,557 | 562,415 |
| BONNEFOY LUC | 16.76 | - | 16,778 | 281,199 |
| ELDESSOUKY SAM | 16.76 | - | 50,335 | 843,615 |
| HASHAD YEHIA | 16.76 | - | 20,973 | 351,507 |
| MUNSCH FREDERICK | 16.76 | 16.83 | -43,809 | -737,942 |
| SAUNDERS BRENT L | 16.76 | 16.76 | 277,648 | 4,653,380 |
| STEWART ANDREW J. | 16.76 | - | 16,778 | 281,199 |
| VON ESCHENBACH ANDREW C. | - | 16.57 | -18,559 | -306,045 |
| Aggregate Net Quantity | 353,701 | |||
| Aggregate Net Value ($) | 5,929,330 | |||
| Aggregate Avg. Buy ($) | 16.76 | |||
| Aggregate Avg. Sell ($) | 16.68 | |||
| Insider Range ($) | ||||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MUNSCH FREDERICK | Officer | 10 Aug 2026 | Sell (-) | 52,900 | 16.83 | 890,307 |
| VON ESCHENBACH ANDREW C. | Director | 07 Aug 2026 | Sell (-) | 6,059 | 16.78 | 101,670 |
| VON ESCHENBACH ANDREW C. | Director | 06 Aug 2026 | Sell (-) | 12,500 | 16.35 | 204,375 |
| SAUNDERS BRENT L | Officer | 05 Aug 2026 | Disposed (-) | 4,231 | 16.76 | 70,912 |
| SAUNDERS BRENT L | Officer | 05 Aug 2026 | Acquired (+) | 281,879 | 16.76 | 4,724,292 |
| BAILEY A ROBERT D | Officer | 05 Aug 2026 | Acquired (+) | 33,557 | 16.76 | 562,415 |
| BONNEFOY LUC | Officer | 05 Aug 2026 | Acquired (+) | 16,778 | 16.76 | 281,199 |
| ELDESSOUKY SAM | Officer | 05 Aug 2026 | Acquired (+) | 50,335 | 16.76 | 843,615 |
| HASHAD YEHIA | Officer | 05 Aug 2026 | Acquired (+) | 20,973 | 16.76 | 351,507 |
| MUNSCH FREDERICK | Officer | 05 Aug 2026 | Acquired (+) | 9,091 | 16.76 | 152,365 |
| STEWART ANDREW J. | Officer | 05 Aug 2026 | Acquired (+) | 16,778 | 16.76 | 281,199 |
| Show more | ||||||
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |